Phaseline

Targets › RT

RT: drug programs, companies and trials

7 programs from 3 companies in 67 trials: 24 Phase 3, 20 Phase 2, 17 Phase 4, 6 Phase 1; Infectious disease, Oncology, Metabolic and endocrine; next expected readout Mar 2027.

Open in Phaseline: the race on RT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GSKDolutegravir
Human immunodeficiency virus type 1 integrase inhibitor
INSTI, RTASE, INTEGRASE, RTPhase 3HIV; HIV Infections; HIV-1-infection; Acute HIV Infection …Mar 2027
GSKLamivudine
Human immunodeficiency virus type 1 reverse transcriptase inhibitor; DNA polymerase/reverse transcriptase inhibitor
RTPhase 3HIV; HIV Infection; HIV Prevention; Pre-exposure Prophylaxis …Mar 2027
Merck & Co. (MSD)Islatravir
Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLG, RTPhase 3HIV-1 Infection; HIV Infection; Human Immunodeficiency Virus Type 1 (HIV-1) InfectionAug 2027
Gilead SciencesIslatravir
Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor
RT, IN, POLB, INTS1, INTS8Phase 3HIV-1-Infection; HIV-1-infection; HIV-1 InfectionMar 2028
GSKRilpivirine
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
RTPhase 3HIV Infections; Infection, Human Immunodeficiency Virus; HIV-1 Infected Adults With Controlled Viremia; HIV -1 Infection …Jun 2028
Merck & Co. (MSD)Doravirine
Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator
RT, POLA2, POLGPhase 3HIV-1 Infection; Human Immunodeficiency Virus (HIV) Infection; HIV-1-infection; HIV …Jul 2028
Gilead SciencesTenofovir Alafenamide
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLRMT, RTPhase 2Acquired Immune Deficiency Syndrome (AIDS); Chronic Hepatitis B; Hepatitis B Reactivation; Chronic Hepatitis b …Mar 2027

Conditions

HIV-1-infection (13) HIV-1 Infection (7) HIV Infections (7) HIV (5) Chronic Hepatitis b (3) HIV Infection (2) Human Immunodeficiency Virus Type 1 (HIV-1) Infection (2) Human Immunodeficiency Virus (HIV) Infection (2) Hepatitis B (2) HIV-1-Infection (1) Acute HIV Infection (1) Healthy Volunteer (1)

Modalities

small molecule (6), mixed (1)

Companies

GSK (3) Gilead Sciences (2) Merck & Co. (MSD) (2)

Related targets

POLG (2) IN (1) POLB (1) INTS1 (1) INTS8 (1) INSTI (1) RTASE (1) INTEGRASE (1) POLA2 (1) POLRMT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.